Companion Diagnostics Market Size, Top Share, Forecast to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Companion Diagnostics Market Size Analysis

Global Companion Diagnostics Market Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-generation Sequencing (NGS)
  1. By Value
4. Immunohistochemistry
  1. By Value
5. In Situ Hybridization
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Central Nervous System Disorders
  1. By Value
6. Virology Diseases
  1. By Value
7. Others
  1. By Value

North America Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-generation Sequencing (NGS)
  1. By Value
4. Immunohistochemistry
  1. By Value
5. In Situ Hybridization
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Central Nervous System Disorders
  1. By Value
6. Virology Diseases
  1. By Value
7. Others
  1. By Value
U.S.
1. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Next-generation Sequencing (NGS)
    1. By Value
  4. Immunohistochemistry
    1. By Value
  5. In Situ Hybridization
    1. By Value
  6. Others
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Central Nervous System Disorders
    1. By Value
  6. Virology Diseases
    1. By Value
  7. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-generation Sequencing (NGS)
  1. By Value
4. Immunohistochemistry
  1. By Value
5. In Situ Hybridization
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Central Nervous System Disorders
  1. By Value
6. Virology Diseases
  1. By Value
7. Others
  1. By Value
U.K.
1. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Next-generation Sequencing (NGS)
    1. By Value
  4. Immunohistochemistry
    1. By Value
  5. In Situ Hybridization
    1. By Value
  6. Others
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Central Nervous System Disorders
    1. By Value
  6. Virology Diseases
    1. By Value
  7. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-generation Sequencing (NGS)
  1. By Value
4. Immunohistochemistry
  1. By Value
5. In Situ Hybridization
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Central Nervous System Disorders
  1. By Value
6. Virology Diseases
  1. By Value
7. Others
  1. By Value
China
1. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Next-generation Sequencing (NGS)
    1. By Value
  4. Immunohistochemistry
    1. By Value
  5. In Situ Hybridization
    1. By Value
  6. Others
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Central Nervous System Disorders
    1. By Value
  6. Virology Diseases
    1. By Value
  7. Others
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-generation Sequencing (NGS)
  1. By Value
4. Immunohistochemistry
  1. By Value
5. In Situ Hybridization
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Central Nervous System Disorders
  1. By Value
6. Virology Diseases
  1. By Value
7. Others
  1. By Value
UAE
1. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Next-generation Sequencing (NGS)
    1. By Value
  4. Immunohistochemistry
    1. By Value
  5. In Situ Hybridization
    1. By Value
  6. Others
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Central Nervous System Disorders
    1. By Value
  6. Virology Diseases
    1. By Value
  7. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Next-generation Sequencing (NGS)
  1. By Value
4. Immunohistochemistry
  1. By Value
5. In Situ Hybridization
  1. By Value
6. Others
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Central Nervous System Disorders
  1. By Value
6. Virology Diseases
  1. By Value
7. Others
  1. By Value
Brazil
1. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Next-generation Sequencing (NGS)
    1. By Value
  4. Immunohistochemistry
    1. By Value
  5. In Situ Hybridization
    1. By Value
  6. Others
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Central Nervous System Disorders
    1. By Value
  6. Virology Diseases
    1. By Value
  7. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Companion Diagnostics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Abbott
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Agilent Technologies
Hoffmann-La Roche Ltd
Biomerieux SA
Qiagen NV
Almac Group
Danaher Corporation
Illumina, Inc.
Myriad Genetics, Inc.
Sysmex Corporation
Thermo Fisher Scientific Inc.
Abnova Corporation
Guardant Health, Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment